Acura Pharmaceuticals, Inc. (ACUR)

Acura Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Revenue	1.56	3.57	2.66	0.41	2.97
Revenue Growth (YoY)	-56.22%	34.36%	548.05%	-86.18%	-33.56%
Cost of Revenue	1.52	1.78	1.51	1.76	3.85
Gross Profit	0.04	1.79	1.15	-1.35	-0.88
Selling, General & Admin	1.25	1.88	1.88	2.57	4.34
Operating Expenses	1.25	1.88	1.88	2.57	4.34
Operating Income	-1.21	-0.09	-0.73	-3.92	-5.23
Interest Expense	-0.2	-0.45	-0.46	-0.4	-0.6
Interest & Investment Income	-	-	0.01	0.17	0
EBT Excluding Unusual Items	-1.41	-0.54	-1.17	-4.14	-5.82
Asset Writedown	-	-0.67	-	-	-
Other Unusual Items	0.54	-	-2.6	0.3	-
Pretax Income	-0.88	-1.21	-3.77	-3.84	-5.82
Income Tax Expense	-	-	-	-	-0.14
Net Income	-0.88	-1.21	-3.77	-3.84	-5.68
Net Income to Common	-0.88	-1.21	-3.77	-3.84	-5.68
Shares Outstanding (Basic)	57	32	27	21	16
Shares Outstanding (Diluted)	57	32	27	21	16
Shares Change (YoY)	75.75%	20.96%	26.36%	32.97%	33.98%
EPS (Basic)	-0.02	-0.04	-0.14	-0.18	-0.36
EPS (Diluted)	-0.02	-0.04	-0.14	-0.18	-0.36
Free Cash Flow	-0.74	-0.72	-0.62	-3.91	-4.51
Free Cash Flow Per Share	-0.01	-0.02	-0.02	-0.18	-0.28
Gross Margin	2.50%	50.11%	43.36%	-	-29.77%
Operating Margin	-77.67%	-2.52%	-27.29%	-954.88%	-176.16%
Profit Margin	-56.24%	-33.84%	-142.04%	-937.07%	-191.57%
Free Cash Flow Margin	-47.47%	-20.14%	-23.26%	-953.17%	-152.06%
EBITDA	-1.14	0.04	-0.45	-3.64	-4.93
EBITDA Margin	-73.00%	0.98%	-17.01%	-	-166.25%
D&A For EBITDA	0.07	0.13	0.27	0.28	0.29
EBIT	-1.21	-0.09	-0.73	-3.92	-5.23
EBIT Margin	-77.67%	-2.52%	-27.29%	-	-176.16%
Revenue as Reported	1.56	3.57	2.66	0.41	2.97

Source: S&P Global Market Intelligence. Standard template. Financial Sources.